NoNO’s initial focus is stroke. Nerinetide and its subsequent analogs have been tailored to offer opportunities for a better life to increasingly large numbers of people who have experienced a stroke. We anticipate a registration-ready package for our initial indication upon completion of ESCAPE-NEXT for people experiencing an acute ischemic stroke, followed by expansion to those also receiving thrombolytics, to those treated outside a hospital setting, and ultimately to the majority of the 101 million stroke survivors who remain on the road to recovery.
NoNO’s pipeline delivers on the promise of neuroprotection and neurorestoration across a broad range of indications. The same fundamental new mechanism in neuroscience of PSD-95 inhibition that offers opportunities for a better life to people following stroke may benefit people who have experienced other brain injuries. Researchers worldwide have confirmed the potential benefits of PSD-95 inhibition not only in stroke but also subarachnoid hemorrhage, traumatic brain injury and concussion, retinal ischemia and dementia including Alzheimer’s disease.